arrow
E

Evdoxia Hatjiharissi

Aristotle University of Thessaloniki
H指数:28
被引数:3,468

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Patients', clinicians' and research's priorities on important outcomes in multiple myeloma: A mixed-methods study

患者、临床医生和研究者在多发性骨髓瘤重要结局上的优先事项:一项混合方法研究

2026-02-260
OAAI
Real-World Outcomes of Patients with Relapsed/Refractory Multiple Myeloma Treated with Teclistamab and Talquetamab; A Multicenter Analysis from the Greek Myeloma Study Group

真实世界研究中接受teclistamab和talquetamab治疗的复发/难治性多发性骨髓瘤患者的结局;希腊骨髓瘤研究小组的多中心分析

BLOOD
IF23.1
2024-11-050
PRE
Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide-exposed patients after one prior line of therapy: Final results of the phase 2 study DARIA
2024-01-313
OAAI
Prospective phase 2 trial of daratumumab with dexamethasone in patients with relapsed/refractory multiple myeloma and severe renal impairment or on dialysis: The DARE study
2023-06-218
OA
Differences in the immunoglobulin gene repertoires of IgG versus IgA multiple myeloma allude to distinct immunopathogenetic trajectories
2023-02-084
OAAI
Pomalidomide Plus Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World POWERFUL Study
2021-04-052
OAAI
A revised international prognostic score system for Waldenstrom's macroglobulinemia
LEUKEMIA
IF13.4
2019-05-2268
PREAI
Glycosphingolipid synthesis inhibition limits osteoclast activation and myeloma bone disease
2015-04-2742
OA
No significant improvement in the outcome of patients with Waldenstrom's macroglobulinemia treated over the last 25 years
2011-04-2023
OAAI